Prevalence of cardiovascular risk factors in men with stable coronary heart disease in France and Spain.
暂无分享,去创建一个
J. Ruidavets | J. Ferrières | V. Bongard | J. Marrugat | M. Fitó | I. Subirana | J. Vila | J. Sala | D. Carrié | M. Galinier | M. Grau | D. Taraszkiewicz | R. Masiá
[1] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[2] Eric Boerwinkle,et al. The Atherosclerosis Risk in Communities (ARIC) Study , 2011 .
[3] D. Arveiler,et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. , 2009, Archives of cardiovascular diseases.
[4] K. Kotseva,et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries , 2009, The Lancet.
[5] M. J. Medrano,et al. Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española , 2007 .
[6] R. Elosua,et al. Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[7] Inder Singh,et al. High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.
[8] E. Braunwald,et al. Recent trials of lipid lowering , 2007, International journal of clinical practice.
[9] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.
[10] P. Steg,et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. , 2006, Archives of internal medicine.
[11] Deepak L. Bhatt,et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.
[12] J. Hippisley-Cox,et al. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis , 2005, BMJ : British Medical Journal.
[13] M. Pfeffer,et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.
[14] J. Ferrières,et al. Comparison of cardiovascular risk factors and drug use in 14544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[15] S. Yusuf,et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.
[16] J. Ferrières. The French paradox: lessons for other countries , 2003, Heart.
[17] A. Dyer,et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.
[18] P. Whincup,et al. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. , 2003, European heart journal.
[19] Eric J Topol,et al. Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.
[20] A. Dyer,et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .
[21] R. Beaglehole,et al. The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? , 2002, International journal of epidemiology.
[22] J. Ferrières,et al. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey , 2002, Heart.
[23] J. Cosín,et al. Nuevos datos sobre la prevención secundaria del infarto de miocardio en España. Resultados del estudio PREVESE II , 2002 .
[24] M. de Oya,et al. [New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study]. , 2002, Revista espanola de cardiologia.
[25] D. Arveiler,et al. Types of alcoholic beverages and blood lipids in a French population , 2002, Journal of epidemiology and community health.
[26] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[27] J. Willerson,et al. Prospects for cardiovascular research. , 2001, JAMA.
[28] A. Dyer,et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.
[29] J. Marrugat,et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. , 1998, Journal of epidemiology and community health.
[30] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[31] C. Hennekens. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. , 1998, Circulation.
[32] D. Wood. European Action on Secondary Prevention by Intervention to Reduce Events , 1998 .
[33] E. Braunwald. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.
[34] A. Folsom,et al. A Prospective Study of Coronary Heart Disease in Relation to Fasting Insulin, Glucose, and Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 1997, Diabetes Care.
[35] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[36] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[37] M. Medrano,et al. [Coronary disease risk attributable to cardiovascular risk factors in the Spanish population]. , 2007, Revista espanola de cardiologia.
[38] D. Arveiler,et al. Change in cardiovascular risk factors in France, 1985–1997 , 2004, European Journal of Epidemiology.
[39] [Therapeutic management of patients with dyslipidemia. Text of recommendations. September 2000]. , 2001, Journal des maladies vasculaires.
[40] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.